# OnCo record nct03162536 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03162536/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03162536", "NCT03162536" ;
  schema:name "A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)"@en ;
  schema:description "A phase 1/2 trial of Nemtabrutinib in mantle cell lymphoma and diffuse large b-cell lymphoma, run by ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA), active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03162536/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03162536> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2017-06-26" ;
  onco:cancers <https://onco.cc/cancers/mantle-cell-lymphoma/>, <https://onco.cc/cancers/dlbcl/>, <https://onco.cc/cancers/follicular-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/nemtabrutinib/> ;
  onco:companies <https://onco.cc/companies/merck/> .